SYNERGISTIC EFFECT OF GALANTAMINE CARRIED ON A NOVEL NANO-DRUG DELIVERY SYSTEM ON INDUCED HEART DISORDERS IN ALZHEIMER’S DISEASE

Journal Title: European Journal of Biomedical and Pharmaceutical Sciences - Year 2017, Vol 4, Issue 10

Abstract

Background: Alzheimer's disease AD, the most common form of dementia, usually presents with cardiac disorders including heart failure. The aim of the present study was to verify that the curative role of Galantamine (the major therapeutic drug for AD) coated with Ce/Ca-HAp (nano-drug delivery particle) on brain tissue is capable of inducing similar therapeutic capabilities in heart disorders besides its role in AD therapy. Presentation of multiple biomarkers (CK, LDH, AST, H-FABP, TAC, TOC, TNO, Na+/ATPase, Ca2+ATPase and Mg2+ ATPase) for heart disorders may induce early detection thus adding to the efficacy of the curative competence. Methods: 70 adult female albino Wistar rats (189- 200 gm) were allotted into 5 groups: Control: Gonad intact rats (8). b) Galantamine (Gal): Gonad intact rats (8) treated with galantamine. c) Alzheimer (Alz): Ovariectomized rats (22) treated orally with AlCl3 (17 mg/kg b.wt) daily for 2 months following one month surgery. d) Alz + Gal rats (16) e) Alz + Gal. + Ce/Ca-HAp rats (16). Results: Results verified marked increases in levels of CK, LDH, AST enzymes, NO, H-FABP, TOC, Ca2+ATPase and Mg2+ ATPase while TAC and TNO and Na+/ATPase levels were significantly decreased in AD rats. Histologically, intramyocardial deposits of A𝛽 peptides; narrowing of cardiac valves; increase in inflammatory cells monocytes, leucocytes and lymphocytes were viewed. Histochemically increase in total protein content and Ca ions were recorded. Marked improvements were more pronounced following GAL therapy coated with Ce/Ca-HAp than GAL alone. Conclusion: In conclusion, as cardiac damage highly presents with AD thus early detection using different biomarkers as cardiac profile (CK, LDH, AST and H-FABP) antioxidant and oxidative status (TAC, TOC and TNO) and ATPase profile (NKA, Ca2+-ATPase and Mg2+-ATPase) is vital for curative competence. Again as Ce/Ca-HAp nanoparticle presented as coating for GAL drug therapy, more promising ameliorative measures could be achieved.

Authors and Affiliations

Shewikar Tewfik El-Bakry

Keywords

Related Articles

ETHYL ACETATE EXTRACTS OF DATES (PHOENIX DACTYLIFERA L.) SHOW PROTECTIVE EFFECT AGAINST PATHOGENIC MICROBES

In the previous study, we reported dates are of high nutritional values including vitamin and mineral contents. In this study, we investigated the activity of dates against infectious microbes. We used ethyl acetate extr...

A REVIEW ON GENETIC PRINCIPLES OF DRUG RESISTANCE

Drug resistance is the reduction in efficacy of a medication to cure a disease or condition. Today, antibiotic-resistance is rising due to dangerously high levels worldwide and threatening our ability to treat even commo...

PHYTOCHEMICAL SCREENING, ANALYTICAL PROFILE AND GREEN SYNTHESIS OF SILVER NANOPARTICLES OF SENNA ALEXANDRINA MILL

Phytochemical screening of Senna alexandrina Mill leaves extract exhibited the presence of carbohydrates, saponins, alkaloids, glycosides, proteins, flavonoids, tannins and steroids. The percentage of studied elements (w...

ORAL DISINTEGRATING TABLETS(ODTS): A REVIEW

Recently ODT terminology has been approved by United States Pharmacopoeia, British Pharmacopoeia, and Centre for Drug Evaluation and Research (CDER). US FDA defined ODT tablets as “A solid dosage form containing medicina...

HANDHELD DEVICES (HHD) USE AMONG FAMILY MEDICINE RESIDENTS IN RIYADH CITY, KSA

Background: Among health care providers, especially physicians, the use of Handheld Devices (HHD) including smartphones and tablets has evolved since the handheld devices technology keeps improving. There are specific ap...

Download PDF file
  • EP ID EP629064
  • DOI -
  • Views 152
  • Downloads 0

How To Cite

Shewikar Tewfik El-Bakry (2017). SYNERGISTIC EFFECT OF GALANTAMINE CARRIED ON A NOVEL NANO-DRUG DELIVERY SYSTEM ON INDUCED HEART DISORDERS IN ALZHEIMER’S DISEASE. European Journal of Biomedical and Pharmaceutical Sciences, 4(10), 45-55. https://europub.co.uk/articles/-A-629064